This article is more than 5 years old. Information may no longer be current.

Alcon announces US launch of TobraDex ST

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

HUENENBERG, Switzerland — Alcon has launched TobraDex ST ophthalmic suspension in the United States, the company announced in a press release.

TobraDex ST (tobramycin/dexamethasone ophthalmic suspension 0.3/0.05%) is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or risk for infection exists, according to the release.

"This product was specifically designed to increase retention time on the eye, allowing the drug to calm inflammation and fight bacteria effectively," Stuart Raetzman, Alcon's vice president of global marketing and U.S. area president, said in the release. "Clinical studies indicated that 10 minutes after dosing, concentrations of TobraDex ST remained on the ocular surface at levels high enough to kill 99.9% of ocular bacteria."

The most commonly reported side effects after use of the compound include eye pain, eyelid itching, eyelid swelling, eye redness and possible IOP increases, the release said.